China SXT Pharmaceuticals
SXTCChina SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) is a specialty pharmaceutical company based in China. Its primary business focus is the research, development, manufacturing, and commercialization of Traditional Chinese Medicine (TCM) products and generic pharmaceutical drugs. The company operates within the biotech and pharmaceuticals sectors, integrating TCM with modern pharmaceutical science. The company’s activities are centered on two main categories. The first is its portfolio of TCM products, which includes treatments derived from traditional formulas and ingredients. The second is its line of generic drugs, which are bioequivalent to existing branded pharmaceuticals. Key therapeutic areas for its products include conditions related to the cardiovascular, central nervous, digestive, and metabolic systems. As a publicly traded entity, China SXT Pharmaceuticals manufactures its products and conducts research and development activities through its operating subsidiaries in China. The company’s strategy involves leveraging the established market for TCM while also participating in the generic drug sector. Its operations encompass the full pharmaceutical value chain from initial research to final sales and distribution.
SXTC · Stock Price
Historical price data
About
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) is a specialty pharmaceutical company based in China. Its primary business focus is the research, development, manufacturing, and commercialization of Traditional Chinese Medicine (TCM) products and generic pharmaceutical drugs. The company operates within the biotech and pharmaceuticals sectors, integrating TCM with modern pharmaceutical science. The company’s activities are centered on two main categories. The first is its portfolio of TCM products, which includes treatments derived from traditional formulas and ingredients. The second is its line of generic drugs, which are bioequivalent to existing branded pharmaceuticals. Key therapeutic areas for its products include conditions related to the cardiovascular, central nervous, digestive, and metabolic systems. As a publicly traded entity, China SXT Pharmaceuticals manufactures its products and conducts research and development activities through its operating subsidiaries in China. The company’s strategy involves leveraging the established market for TCM while also participating in the generic drug sector. Its operations encompass the full pharmaceutical value chain from initial research to final sales and distribution.